Indications, complications, and outcomes following surgical management of locally advanced and metastatic renal cell carcinoma

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Gill IS, Aron M, Gervais DA, et al. Small renal mass. N Eng J Med. 2010;362:624–634.
   PubMed Web of Science ®Google Scholar
• Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193–205.
   PubMed Web of Science ®Google Scholar
• Sorbellini M, Bratlavsky G. Renal cell carcinoma and prognostic factors predictive of survival. Urology. 2010;17:362–363.
   Google Scholar
• Guidelines on renal cell carcinoma. European Association of Urology, 2017. cited 2017 Dec 30. Available from: http://www.uroweb.org/guideline/renal-cell-carcinoma
   Google Scholar
• Adibi M, Thomas AZ, Borregales LD, et al. Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol. 2015;33:528–537.
   PubMed Web of Science ®Google Scholar
• Kenney PA, Wood CG. Integration of surgery and systemic therapy for renal cell carcinoma. Urol Clin North Am. 2012;39:211–231.
   PubMed Web of Science ®Google Scholar
• Joyce DD, Psutka SP, Groeschl RT, et al. Complications and outcomes associated with surgical management of renal cell carcinoma involving the liver: a matched cohort study. Urology. 2017;99:155–161.
   PubMed Web of Science ®Google Scholar
• Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969;101:297–301.
   PubMed Web of Science ®Google Scholar
• Hoffman NE, Gillet MD, Cheville JC. Difference in organ system of distant metastses by mRCC subtypes. J Urol. 2008;180:474–477.
   Google Scholar
• Marcus SG, Choyke PL, Reiter R. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol. 1993;150:463–466.
   PubMed Web of Science ®Google Scholar
• Motzen RJ, Russo P. Systemic therapy for renal cancer. J Urol. 2000;163:408–417.
   PubMed Web of Science ®Google Scholar
• Mickisch GH. Principles of nephrectomy for malignant disease. BJU Int. 2002;89:488–495.
   PubMed Web of Science ®Google Scholar
• deKernion JB, Ramming KP, Smith RB. The natural history of mRCC: a computer analysis. J Urol. 1978;120:148–152.
   PubMed Web of Science ®Google Scholar
• Walther MM, Patel B, Choyka PL, et al. Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation. J Urol. 1997;158:733–739.
   PubMed Web of Science ®Google Scholar
• Pardoll D. Does the immune system see tumors as foreign or self? Ann Rev Immunol. 2003;21:807–839.
   PubMed Web of Science ®Google Scholar
• Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64:2205–2211.
   PubMed Web of Science ®Google Scholar
• Kowalczyk D, Skorupski W, Kwias Z, et al. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol. 1997;80:543–547.
   PubMedGoogle Scholar
• Dadian G, Riches PG, Henderson DC, et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol. 1994;74:15–22.
   PubMedGoogle Scholar
• Uzzo RG, Clark PE, Rayman P, et al. Alterations in NF-kappa B activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst. 1999;91:718–721.
   PubMedGoogle Scholar
• Gatenby RA, Gawlinski ET, Tangen CM, et al. The possible role in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res. 2002;62:5218–5222.
   PubMed Web of Science ®Google Scholar
• Belldegrun A, Koo AS, Bochner B, et al. Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy. Eur Urol. 1990;18:42–45.
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferonalfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659.
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Tangen CM, Conlon SJ, et al. Predictors of survival of advanced renal cell carcinoma: long-term results from southwest oncology group trial S8949. J Urol. 2009;181:512–516.
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferon-alfa based immunotherapy compared with interferon-alfa alone in metastatic renal cell carcinoma: a randomized trial. Lancet. 2001;358:966–970.
   PubMed Web of Science ®Google Scholar
• Neves RJ, Zincke H. Surgical treatment of renal cancer with vena cava extension. Br J Urol. 1987;59:390–395.
   PubMedGoogle Scholar
• Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071–1076.
   PubMed Web of Science ®Google Scholar
• Zini L, Capitanio U, Perrotte P, et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology. 2009;73:342–346.
   PubMed Web of Science ®Google Scholar
• Conti SL, Thomas IC, Hagedorn JC, et al. Utilization of cytoreductive nephrectomy and patients survival in the targeted therapy era. Int J Cancer. 2014;134:2245–2252.
   PubMed Web of Science ®Google Scholar
• Hanna N, Sun M, Meyer CP, et al. Survival analysis of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J Clin Oncol. 2016;34:3267–3275.
   PubMed Web of Science ®Google Scholar
• Bromwich E, Hendry A, Aitchinson M. Cytoreductive nephrectomy: is it a realistic option in patients with renal cancer. BJU Int. 2002;89:523–525.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy of survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185:60–66.
   PubMed Web of Science ®Google Scholar
• Culp SH, Tannir NM, Abel EJ. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116:3378–3388.
   PubMed Web of Science ®Google Scholar
• Takagi T, Sugihara T, Yasunaga H, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based analysis of perioperative outcomes according to clinical stage. Int J Urol. 2014;21:770–775.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–463.
   PubMed Web of Science ®Google Scholar
• Donksov F. von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006;24:1997–2005.
   PubMedGoogle Scholar
• Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large multicenter study. J Clin Oncol. 2009;27:5794–5799.
   PubMed Web of Science ®Google Scholar
• McKay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65:577–584.
   PubMed Web of Science ®Google Scholar
• Sharma P, Zargar-Shostari K, Caracciolo JT, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015;33:339e17–23.
   Google Scholar
• Corcoran AT, Kaffenberger SD, Clark PE, et al. Hypoalbuminemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU Int. 2015;116:351–357.
   PubMed Web of Science ®Google Scholar
• Margulis V, Shariat SF, Rapoport Y, et al. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol. 2013;63:947–952.
   PubMed Web of Science ®Google Scholar
• Abel EJ, Spiess PE, Margulis V, et al. Cytoreductive nephrectomy for renal cell carcinoma with venous tumor thrombus. J Urol. 2017;198:281–288.
   PubMed Web of Science ®Google Scholar
• You D, Jeong IG, Song C, et al. Analysis of preoperative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. Jpn J Clin Oncol. 2015;45:96–102.
   PubMed Web of Science ®Google Scholar
• Krajewski KM, Guo M, van den Abbeele AD, et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011;59:856–862.
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa 2a for treatment of metastatic renal cell carcinoma: a radomised, double-blind phase III trial. Lancet. 2016;370:2103–2111.
   Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Eng J Med. 2013;369:722–731.
   PubMed Web of Science ®Google Scholar
• Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alpha and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomized phase 2 trial. Lancet Oncol. 2011;12:673–680.
   PubMed Web of Science ®Google Scholar
• Patel N, Woo J, Liss MA, et al. Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches. Can J Urol. 2016;23:8227–8233.
   PubMed Web of Science ®Google Scholar
• Capitanio U, Zini L, Perrotte P, et al. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology. 2008;72:1090–1095.
   PubMed Web of Science ®Google Scholar
• Babaian KN, Merrill MM, Matin S, et al. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014;192:36–42.
   PubMed Web of Science ®Google Scholar
• Trinh QD, Bianchi M, Hansen J, et al. In-hospital mortality and failure to rescue after cytoreductive nephrectomy. Eur Urol. 2013;63:1107–1114.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Sun M, Thuret R, et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol. 2011;18:2988–2996.
   PubMed Web of Science ®Google Scholar
• Sun M, Abdollah F, Schmittges J, et al. Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA. BJU Int. 2012;109:1807–1812.
   PubMed Web of Science ®Google Scholar
• Cloutier V, Capitanio U, Zini L, et al. Thirty-day mortality after nephrectomy: clinical implications for informed consent. Eur Urol. 2009;56:998–1005.
   PubMed Web of Science ®Google Scholar
• Gonzalez J, Ciancio G. Caval thrombus in conjunction with renal tumors: indication for surgery and technical details. Curr Urol Rep. 2014;15:451.
   PubMed Web of Science ®Google Scholar
• Berg AA. Malignant hypernephroma of the kidney, its clinical course and diagnosis, with a description of the author’s method of radical operative cure. Surg Gynecol Obstet. 1913;17:463–471.
   Google Scholar
• Marshall VF, Middleton RG, Holswade GR, et al. Surgery for renal cell carcinoma in the vena cava. J Urol. 1970;103:414–420.
   PubMed Web of Science ®Google Scholar
• Lardas M, Stewart F, Scrimgeour D, et al. Systematic review of surgical management of nonmetastatic renal cell carcinoma with vena caval thrombus. Eur Urol. 2016;70:265–280.
   PubMed Web of Science ®Google Scholar
• Kirkali Z, Van Poppel H. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol. 2007;52:658–662.
   PubMed Web of Science ®Google Scholar
• Ayyathurai R, Garcia-Roig M, Gorin MA, et al. Bland thrombus association with tumour thrombus in renal cell carcinoma: analysis of surgical significance and role of inferior vena caval interruption. BJU Int. 2012;110:E449–55.
   PubMed Web of Science ®Google Scholar
• Casey RG, Raheem OA, Elmusharaf E, et al. Renal cell carcinoma with IVC and atrial thrombus: a single centre’s 10 year surgical experience. Surgeon. 2013;11:295–299.
   PubMed Web of Science ®Google Scholar
• Abel E, Thompson R, Margulis V, et al. Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. Eur Urol. 2014;66:584–592.
   PubMed Web of Science ®Google Scholar
• Cata JP, Gottumukkala V. Blood loss and massive transfusion in patients undergoing major oncological surgery: what do we know? ISRN Anesthesiology. 2012;2012:1–11. doi:10.5402/2012/918938; Article ID 918938.
   Google Scholar
• Dominik J, Moravek P, Zacek P, et al. Long-term survival after radical surgery for renal cell carcinoma with tumour thrombus extension into the right atrium. BJU Int. 2013;111:E59–64.
   PubMed Web of Science ®Google Scholar
• Jibiki M, Iwai T, Inoue Y, et al. Surgical strategy for treating renal cell carcinoma with thrombus extending into the inferior vena cava. J Vasc Surg. 2004;39:829–835.
   PubMed Web of Science ®Google Scholar
• Gonzalez J, Andres G, Martínez-Salamanca JI, et al. Improving surgical outcomes in renal cell carcinoma involving the inferior vena cava. Expert Rev Anticancer Ther. 2013;13:1373–1387.
   PubMed Web of Science ®Google Scholar
• Blute ML, Leibovich BC, Lohse CM, et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004;94:33–41.
   PubMed Web of Science ®Google Scholar
• Shuch B, Larochelle JC, Onyia T, et al. Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. J Urol. 2009;181:492–498.
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Chao DH, et al. Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? J Urol. 2002;168:962–967.
   PubMed Web of Science ®Google Scholar
• Martínez-Salamanca JI, Huang WC, Millan I, et al. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol. 2011;59:120–127.
   PubMed Web of Science ®Google Scholar
• Westesson KE, Klink JC, Rabets JC, et al. Surgical outcomes after cytoreductive nephrectomy with inferior vena cava thrombectomy. Urology. 2014;84:1414–1419.
   PubMed Web of Science ®Google Scholar
• Patil MB, Montez J, Loh-Doyle J, et al. Level III-IV inferior vena caval thrombectomy without cardiopulmonary bypass: long-term experience with intrapericardial control. J Urol. 2014;192:682–688.
   PubMed Web of Science ®Google Scholar
• Toren P, Abouassaly R, Timilshina N, et al. Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus. Urology. 2013;82:572–577.
   PubMed Web of Science ®Google Scholar
• Ali AS, Vasdev N, Shanmuganathan S, et al. The surgical management of renal cell cancer with IVC tumor thrombus: 15-years of experience using a multi-specialty approach at a single UK referral center. Urol Oncol. 2013;31:1298–1304.
   PubMed Web of Science ®Google Scholar
• Vergho DC, Loeser A, Kocot A, et al. Tumor thrombus of inferior vena cava in patients with renal cell carcinoma-clinical and oncological outcome of 50 patients after surgery. BMC Res Notes. 2012;5:5.
   PubMedGoogle Scholar
• Spiess PE, Kurian T, Lin HY, et al. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. BJU Int. 2012;110:E470–4.
   PubMed Web of Science ®Google Scholar
• Hyams ES, Pierorazio PM, Shah A, et al. Graft reconstruction of inferior vena cava for renal cell carcinoma stage pT3b or greater. Urology. 2011;78:838–843.
   PubMed Web of Science ®Google Scholar
• Zastrow S, Leike S, Oehlschläger S, et al. Surgery for renal cell cancer extending into the inferior vena cava - evaluation of survival and perioperative complications using a standardized classification system. BJU Int. 2011;108:1439–1443.
   PubMed Web of Science ®Google Scholar
• Hefland BT, Smith ND, Kozlowski JM, et al. Ann Vasc Surg. 2011;25:39–43.
   PubMed Web of Science ®Google Scholar
• Kaag MG, Toyen C, Russo P, et al. Radical nephrectomy with vena caval thrombectomy: a contemporary experience. BJU Int. 2011;107:1386–1393.
   PubMed Web of Science ®Google Scholar
• Kulkarni JN, Acharya PU, Rizvi SJ, et al. Surgical management of renal cell carcinoma with inferior vena caval thrombus: a teaching hospital experience. Indian J Cancer. 2007;44:45–50.
   PubMedGoogle Scholar
• Klatte T, Pantuck AJ, Riggs SB, et al. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007;178:1189–1195.
   PubMed Web of Science ®Google Scholar
• Rigaud J, Hetet JF, Braud G, et al. Surgical care, morbidity, mortality and follow-up after nephrectomy for renal cancer with extension of tumor thrombus into the inferior vena cava: retrospective study since 1990s. Eur Urol. 2006;50:302–310.
   PubMed Web of Science ®Google Scholar
• Bastian PJ, Haferkamp A, Akbarov I, et al. Surgical outcome following radical nephrectomy in cases with inferior vena cava tumour thrombus extension. Eur J Surg Oncol. 2005;31:420–423.
   PubMed Web of Science ®Google Scholar
• Parekh DJ, Cookson MS, Chapman W, et al. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes. J Urol. 2005;173:1897–1902.
   PubMed Web of Science ®Google Scholar
• Gallucci M, Borzomati D, Flammia G, et al. Liver harvesting surgical technique for the treatment of retro-hepatic caval thrombosis concomitant to renal cell carcinoma: perioperative and long-term results in 15 patients without mortality. Eur Urol. 2004;45:194–202.
   PubMed Web of Science ®Google Scholar
• Nguyen HG, Tilki D, Dall’era MA, et al. Cardiopulmonary bypass has no significant impact on survival in patients undergoing nephrectomy and level III-IV inferior vena cava thrombectomy: multi-institutional analysis. J Urol. 2015;194:304–308.
   PubMed Web of Science ®Google Scholar
• Sweeney P, Wood CG, Pisters LL, et al. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol. 2003;21:327–333.
   PubMed Web of Science ®Google Scholar
• Haferkamp A, Bastian PJ, Jakobi H, et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term follow up. J Urol. 2007;177:1703–1708.
   PubMed Web of Science ®Google Scholar
• Wagner B, Patard JJ, Mejean A, et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009;55:452–459.
   PubMed Web of Science ®Google Scholar
• Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23:973–980.
   PubMed Web of Science ®Google Scholar
• Jakubowski CD, Vertosick EA, Untch BR, et al. Complete metastasectomy for renal cell carcinoma: comparison of five solid organ sites. J Surg Oncol. 2016;114:375–379.
   PubMed Web of Science ®Google Scholar
• Karam JA, Rini BI, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011;185:439–444.
   PubMed Web of Science ®Google Scholar
• Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117:2873–2882.
   PubMed Web of Science ®Google Scholar
• Dabestani S, Marconi L, Hoffmann F, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15:e549–61.
   PubMed Web of Science ®Google Scholar
• Naito S, Kinoshita H, Kondo T, et al. Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology. 2013;82:846–851.
   PubMed Web of Science ®Google Scholar
• Vogl UM, Zehetgruber H, Dominkus M, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006;95:691–698.
   PubMed Web of Science ®Google Scholar
• Eggener SE, Yossepowitch O, Kundu S, et al. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008;180:873–878.
   PubMed Web of Science ®Google Scholar
• Daliani DD, Tannir NM, Papandreou CN. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 2009;104:456–460.
   PubMed Web of Science ®Google Scholar
• Tosco L, Van Poppel H, Frea B, et al. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol. 2013;63:646–652.
   PubMed Web of Science ®Google Scholar
• Meyer CP, Sun M, Karam JA, et al. Complications after metastasectomy for renal cell carcinoma: a population-based assessment. Eur Urol. 2017;72:171–174.
   PubMed Web of Science ®Google Scholar
• Muth A, Persson F, Jansson S, et al. Prognostic factors for survival after surgery from adrenal metastases. Eur J Surg Oncol. 2010;36:699–704.
   PubMed Web of Science ®Google Scholar
• Vazquez BJ, Richards ML, Lohse CM, et al. Adrenalectomy improves outcomes of selected patients with metastatic carcinoma. World J Surg. 2012;36:1400–1405.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Cozzoli A, Simeone C, et al. Surgical treatment of adrenal metastases from renal cell carcinoma: a single-center experience of 45 patients. BJU Int. 2006;97:505–508.
   PubMed Web of Science ®Google Scholar
• Terrone C, Guercio S, De Luca S, et al. The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int. 2003;91:37–40.
   PubMed Web of Science ®Google Scholar
• Trihn QD, Schmitges J, Bianchi M, et al. Node positive renal cell carcinoma in the absence of distant metastases: predictors of cancer specific mortality in a population-based cohort. BJU Int. 2012;110:E21–7.
   PubMed Web of Science ®Google Scholar
• Gershman B, Moreira DM, Thompson RH, et al. Renal cell carcinoma with isolated lymph node involvement: long-term natural history and predictors of oncologic outcomes following surgical resection. Eur Urol. 2017;72:300–306.
   PubMed Web of Science ®Google Scholar
• Hofmann H-S, Neef H, Krohe K, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005;48:77–82.
   Google Scholar
• Pfannschmidt J, Hoffmann H, Muley T, et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 2002;74:1653–1657.
   PubMed Web of Science ®Google Scholar
• Assouad J, Petkova B, Berna P, et al. Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg. 2007;84:1114–1120.
   PubMed Web of Science ®Google Scholar
• Ruys AT, Tanis PJ, Iris ND, et al. Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol. 2011;18:1932–1938.
   PubMed Web of Science ®Google Scholar
• Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol. 2003;10:705–710.
   PubMed Web of Science ®Google Scholar
• Staehler MD, Kruse J, Haseke N, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol. 2010;28:543–547.
   PubMed Web of Science ®Google Scholar
• Tanis PJ, Van Der Gaag N, Busch ORC, et al. Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg. 2009;96:579–592.
   PubMed Web of Science ®Google Scholar
• Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol. 2009;10:287–293.
   PubMed Web of Science ®Google Scholar
• Woodward E, Jagdev S, McParland L, et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2011;48:160–166.
   PubMed Web of Science ®Google Scholar
• Szendroi A, Dinya E, Kardos M, et al. Prognostic factors and survival of renal cell carcinoma patients with bone metastases. Pathol Oncol Res. 2010;16:29–38.
   PubMed Web of Science ®Google Scholar
• Evenski A, Ramasunder S, Fox W, et al. Treatment and survival of ossous renal cell carcinoma metastases. J Surg Oncol. 2012;106:850–855.
   PubMed Web of Science ®Google Scholar
• Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007;89:1794–1801.
   PubMed Web of Science ®Google Scholar
• Shuch B, La Rochelle JC, Klatte T, et al. Brain metastases from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008;113:1641–1648.
   PubMed Web of Science ®Google Scholar
• Nieder C, Spanne O, Nordoy T, et al. Treatment of brain metastases from renal cell carcinoma. Urol Oncol. 2011;29:405–410.
   PubMed Web of Science ®Google Scholar
• Choi SY, Yoo S, You D, et al. Prognostic factors for survival of patients with synchronous or metachronous brain metastasis of renal cell carcinoma. Clin Genitour Cancer. 2017;15:717–723.
   PubMed Web of Science ®Google Scholar
• Muacevic A, Kreth FW, Horstmann GA, et al. Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurg. 1999;91:35–43.
   PubMed Web of Science ®Google Scholar
• Shuto T, Matsunaga S, Suenaga J, et al. Treatment strategy for metastatic brain tumors from renal cell carcinoma: selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema. J Neuroloncol. 2010;98:169–175.
   PubMed Web of Science ®Google Scholar
• Brehmer B, Kauffmann C, Blank C, et al. Resection of metastases and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of local control and outcome. World J Urol. 2016;34:1061–1066.
   PubMed Web of Science ®Google Scholar